TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Evaluate Freezed-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients
Brief Summary: Knowledge and management of bleeding in severe trauma has changed. A specific coagulopathy is present in 40% of cases. It has a very early onset and this coagulopathy is associated with increased mortality. It must be detected and treated early, as illustrated by the military medical data, from the Iraq war and civilian medicine. However, fresh frozen plasma (FFP) requires a thawing step.The French army has encouraged the development of a freeze-dried plasma of innovative because viral inactivation and universal blood grouping, well tolerated, with a reduced risk of TRALI. This sophisticated therapeutic product can be administered after 6 minutes of reconstitution without the need for cross-matching. Nevertheless, its used is currently reserved for military purpose in overseas operations and needs to be evaluated for civil use. To this end, the investigators need to evaluate the impact on coagulopathy of an immediate availability of plasma.


Options:
A: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution
B: Arm Label: Freezed-dried plasma; Type: EXPERIMENTAL; Interventions: Drug: Freezed-dried plasma | Arm Label: Fresh-frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh-frozen plasma | Intervention Type: DRUG; Name: Freezed-dried plasma; Assigned to Arm(s): Freezed-dried plasma | Intervention Type: DRUG; Name: Fresh-frozen plasma; Assigned to Arm(s): Fresh-frozen plasma
C: Arm Label: Group A: RiaSTAP; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Group B: apheresis platelets; Type: ACTIVE_COMPARATOR; Interventions: Other: apheresis platelets | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Group A: RiaSTAP | Intervention Type: OTHER; Name: apheresis platelets; Assigned to Arm(s): Group B: apheresis platelets
D: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease
Brief Summary: This study aims to examine the safety and efficacy of suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD). The primary hypothesis for the study is that suvorexant is superior to placebo in improving insomnia as measured by change from baseline in polysomnography (PSG)-derived total sleep time (TST) at Week 4.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Gabapentin Enacarbil (GEn); Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Enacarbil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Gabapentin Enacarbil; Assigned to Arm(s): Gabapentin Enacarbil (GEn) | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Condition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized Social Activities (ISA) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Resistance Training and Walking (PRT/walking) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Combined ISA/PRT/walking | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individualized Social Activities (ISA); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Physical Resistance Training and Walking (PRT/walking); Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Combined ISA/PRT/walking; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease
Brief Summary: This study aims to examine the safety and efficacy of suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD). The primary hypothesis for the study is that suvorexant is superior to placebo in improving insomnia as measured by change from baseline in polysomnography (PSG)-derived total sleep time (TST) at Week 4.


Options:
A: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Suvorexant HD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant High Dose (HD) | Arm Label: Suvorexant LD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant Low Dose (LD) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Suvorexant High Dose (HD); Assigned to Arm(s): Suvorexant HD | Intervention Type: DRUG; Name: Suvorexant Low Dose (LD); Assigned to Arm(s): Suvorexant LD | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Melatonin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Melatonin 5 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Melatonin 5 mg; Assigned to Arm(s): Melatonin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Effects of Combined Exercise and Oscillatory Positive Expiratory Pressure Therapy on Sputum Properties and Lung Diffusion Capacity in Cystic Fibrosis: a Randomized Crossover Trial
Brief Summary: The investigators aim to compare a single bout of moderately intense cycling exercise incorporating Flutter® breathing maneuvers with a single bout of moderately intense cycling exercise alone on sputum viscoelasticity (primary endpoint) and the diffusion capacity of the lungs in adult patients with cystic fibrosis.

The investigators further aim to analyze the short-term variability of resting diffusion capacity of carbon monoxide (DLCO) and nitric oxide (DLNO) in patients with cystic fibrosis.


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
C: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
D: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Effects of Combined Exercise and Oscillatory Positive Expiratory Pressure Therapy on Sputum Properties and Lung Diffusion Capacity in Cystic Fibrosis: a Randomized Crossover Trial
Brief Summary: The investigators aim to compare a single bout of moderately intense cycling exercise incorporating Flutter® breathing maneuvers with a single bout of moderately intense cycling exercise alone on sputum viscoelasticity (primary endpoint) and the diffusion capacity of the lungs in adult patients with cystic fibrosis.

The investigators further aim to analyze the short-term variability of resting diffusion capacity of carbon monoxide (DLCO) and nitric oxide (DLNO) in patients with cystic fibrosis.


Options:
A: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Wellness | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Wellness; Assigned to Arm(s): 2
C: Arm Label: Endurance respiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Endurance respiratory muscle training | Arm Label: Resistance inspiratory muscle training; Type: ACTIVE_COMPARATOR; Interventions: Other: Resistance inspiratory muscle training | Intervention Type: OTHER; Name: Endurance respiratory muscle training; Assigned to Arm(s): Endurance respiratory muscle training | Intervention Type: OTHER; Name: Resistance inspiratory muscle training; Assigned to Arm(s): Resistance inspiratory muscle training
D: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Effects of Combined Exercise and Oscillatory Positive Expiratory Pressure Therapy on Sputum Properties and Lung Diffusion Capacity in Cystic Fibrosis: a Randomized Crossover Trial
Brief Summary: The investigators aim to compare a single bout of moderately intense cycling exercise incorporating Flutter® breathing maneuvers with a single bout of moderately intense cycling exercise alone on sputum viscoelasticity (primary endpoint) and the diffusion capacity of the lungs in adult patients with cystic fibrosis.

The investigators further aim to analyze the short-term variability of resting diffusion capacity of carbon monoxide (DLCO) and nitric oxide (DLNO) in patients with cystic fibrosis.


Options:
A: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: High Intensity Interval Training; Type: EXPERIMENTAL; Interventions: Other: Educational intervention, Other: Aerobic exercise | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational intervention | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Control Group, High Intensity Interval Training | Intervention Type: OTHER; Name: Aerobic exercise; Assigned to Arm(s): High Intensity Interval Training
D: Arm Label: 1. Exercise testing and self drainage session; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: 2. Chest physiotherapy (CP) session; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): 1. Exercise testing and self drainage session, 2. Chest physiotherapy (CP) session

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Brief Summary: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.


Options:
A: Arm Label: Arm 1: Health Education Program; Type: OTHER; Interventions: Other: Health Education Program | Arm Label: Arm 2: Health Education Program + Weight Loss Intervention; Type: OTHER; Interventions: Other: Health Education Program, Other: Weight Loss Intervention | Intervention Type: OTHER; Name: Health Education Program; Assigned to Arm(s): Arm 1: Health Education Program, Arm 2: Health Education Program + Weight Loss Intervention | Intervention Type: OTHER; Name: Weight Loss Intervention; Assigned to Arm(s): Arm 2: Health Education Program + Weight Loss Intervention
B: Arm Label: aerobic resistance; Type: EXPERIMENTAL; Interventions: Behavioral: aerobic resistance exercise | Arm Label: home based physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: home based health promotion | Intervention Type: BEHAVIORAL; Name: aerobic resistance exercise; Assigned to Arm(s): aerobic resistance | Intervention Type: BEHAVIORAL; Name: home based health promotion; Assigned to Arm(s): home based physical activity
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Resistance and aerobic training | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Aerobic training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard supportive care | Intervention Type: OTHER; Name: Resistance and aerobic training; Assigned to Arm(s): Group 1 | Intervention Type: OTHER; Name: Aerobic training; Assigned to Arm(s): Group 2 | Intervention Type: OTHER; Name: Standard supportive care; Assigned to Arm(s): Group 3
D: Arm Label: SG-WLP; Type: OTHER; Interventions: Behavioral: SG-WLP | Arm Label: MF-WLP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MF-WLP | Intervention Type: BEHAVIORAL; Name: MF-WLP; Assigned to Arm(s): MF-WLP | Intervention Type: BEHAVIORAL; Name: SG-WLP; Assigned to Arm(s): SG-WLP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities
Brief Summary: Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. Until now, the lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. The aim of this study was to determine whether a lower dosage of metformin, such as 500 mg/d, is effective for improving metabolic profiles in clozapine-treated patients with pre-existing metabolic abnormalities.

Methods:

In this 12-week, randomized, double-blind, placebo-controlled trial, metformin 500 mg/d or 1000 mg/d or a placebo was prescribed to clozapine-treated patients with schizophrenia having pre-existing metabolic abnormalities. The recruited patients underwent physical and laboratory evaluations at week-4, week-8, and week-12.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: metformin 500 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: metformin 1000 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: placebo; clozapine 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Intervention Type: DRUG; Name: metformin 500 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg | Intervention Type: DRUG; Name: clozapine 100 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Liraglutide placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide Placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Liraglutide Placebo; Assigned to Arm(s): Liraglutide placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure.A Comparative Study
Brief Summary: 300 recurrent implantation failure patients will be alternatively assigned to assisted hatching , endometrial scratch , and no treatment ,100 patients in each group


Options:
A: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Induced endometrial injury arm; Type: EXPERIMENTAL; Interventions: Device: Pipelle de Cornier® | Intervention Type: DEVICE; Name: Pipelle de Cornier®; Assigned to Arm(s): Induced endometrial injury arm
B: Arm Label: Control - Standard ART treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test - PGS; Type: EXPERIMENTAL; Interventions: Genetic: Next Generation Sequencing after Blastocyst biopsy | Intervention Type: GENETIC; Name: Next Generation Sequencing after Blastocyst biopsy; Assigned to Arm(s): Test - PGS
C: Arm Label: With PGS 2.0; Type: EXPERIMENTAL; Interventions: Procedure: IVF/ICSI, Genetic: PGS 2.0 | Arm Label: Without PGS 2.0; Type: ACTIVE_COMPARATOR; Interventions: Procedure: IVF/ICSI, Other: Conventional embryo morphology evaluation | Intervention Type: PROCEDURE; Name: IVF/ICSI; Assigned to Arm(s): With PGS 2.0, Without PGS 2.0 | Intervention Type: GENETIC; Name: PGS 2.0; Assigned to Arm(s): With PGS 2.0 | Intervention Type: OTHER; Name: Conventional embryo morphology evaluation; Assigned to Arm(s): Without PGS 2.0
D: Arm Label: Endometrial scratch group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endometrial scratch, Procedure: controlled ovarian hyperstimulation | Arm Label: Assisted hatching group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: assisted hatching, Procedure: controlled ovarian hyperstimulation | Arm Label: ovarian stimulation only group; Type: SHAM_COMPARATOR; Interventions: Procedure: controlled ovarian hyperstimulation | Intervention Type: PROCEDURE; Name: endometrial scratch; Assigned to Arm(s): Endometrial scratch group | Intervention Type: PROCEDURE; Name: assisted hatching; Assigned to Arm(s): Assisted hatching group | Intervention Type: PROCEDURE; Name: controlled ovarian hyperstimulation; Assigned to Arm(s): Assisted hatching group, Endometrial scratch group, ovarian stimulation only group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Patients With Complex Regional Pain Syndrome Comparing Graded Motor Imagery and Desensitization Versus Simple Desensitization and Changes in Resting-State Connectivity of Cerebral Networks Before and After Treatment.
Brief Summary: The intention of this trial is to investigate whether combined Graded Motor Imagery (GMI) and Desensitization (D) among patients with CRPS is clinically more effective than only D and to study changes in connectivity in the Default Mode Network before and after treatment.


Options:
A: Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
C: Arm Label: TENS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Transcutaneous electrical nerve stimulation | Arm Label: TENS and hypnosis.; Type: EXPERIMENTAL; Interventions: Behavioral: Transcutaneous electrical nerve stimulation and hypnosis | Intervention Type: BEHAVIORAL; Name: Transcutaneous electrical nerve stimulation; Assigned to Arm(s): TENS | Intervention Type: BEHAVIORAL; Name: Transcutaneous electrical nerve stimulation and hypnosis; Assigned to Arm(s): TENS and hypnosis.
D: Arm Label: GMI and Desensitization; Type: EXPERIMENTAL; Interventions: Behavioral: GMI and Desensitization | Arm Label: Desensitization; Type: EXPERIMENTAL; Interventions: Behavioral: Desensitization | Intervention Type: BEHAVIORAL; Name: GMI and Desensitization; Assigned to Arm(s): GMI and Desensitization | Intervention Type: BEHAVIORAL; Name: Desensitization; Assigned to Arm(s): Desensitization

Answer: D